Cell Medica Acquires WT1 Cancer Immunotherapy from CGT Catapult – Drug Discovery & Development
Drug Discovery & Development |
Cell Medica Acquires WT1 Cancer Immunotherapy from CGT Catapult
Drug Discovery & Development Cell Medica announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult's GMP … |
